TherapeuticsMD (TXMD) Total Current Liabilities (2010 - 2026)

TherapeuticsMD (TXMD) has reported Total Current Liabilities for 17 consecutive years, with $5.0 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Total Current Liabilities rose 7.31% year-over-year to $5.0 million; the trailing twelve-month figure through Jun 2026 stood at $5.0 million (up 7.31% YoY), and the FY2025 full-year result was $4.8 million, down 7.38% from the prior year.
• Total Current Liabilities climbed to $5.0 million in Q2 2026 per TXMD's latest filing, from $4.9 million in the prior quarter.
• Across five years, Total Current Liabilities topped out at $264.8 million in Q1 2022 and bottomed at $4.7 million in Q2 2025.
• Historically, Total Current Liabilities has averaged $42.1 million across 5 years, with a median of $6.2 million in 2024.
• The sharpest annual moves came in 2022 and 2023: Total Current Liabilities soared 332.14% in 2022, then tumbled 92.7% in 2023.
• Over 5 years, Total Current Liabilities stood at $46.8 million in 2022, then sank by 85.37% to $6.9 million in 2023, then dropped by 24.63% to $5.2 million in 2024, then retreated by 7.38% to $4.8 million in 2025, then advanced by 4.56% to $5.0 million in 2026.
• According to Business Quant data, Total Current Liabilities over the past three periods registered $5.0 million, $4.9 million, and $4.8 million for Q2 2026, Q1 2026, and Q4 2025 respectively.